- €2.57m
- €19.17m
- €33.25m
Brief: Paion AG Announces Fully Underwritten Rights Issue Of Almost EUR 8 Mln & Publishes Preliminary, Unaudited Key Group Financials For 2020
Brief: Paion Grants Exclusive License To TTY Biopharm
Brief: Paion Gets Positive CHMP Opinion Recommending Approval Of Byfavo(R) In Procedural Sedation
Brief: Paion Says Acacia Pharma Launches Byfavo(Tm) In U.S.
La Jolla: Surges on Europe deal for blood pressure, abdominal infection treatments
Brief: Paion Announces Licensing Agreement With La Jolla Pharmaceutical
Brief: Paion - NDA Approval Of Byfavo In South Korea
Brief: Paion Says Juergen Beck Will Leave Management Board On Dec. 31
Brief: Paion AG Reports Positive Remimazolam Topline Data In EU Phase III Trial In General Anesthesia
Brief: Paion 9-month Net Profit At EUR 5.7 Mln
Brief: Paion To Market Byfavo In United States By End-202
Brief: Paion H1 Net Profit Turns To Loss Of EUR 6.1 Million
Brief: Paion's Chinese Remimazolam Licensee Launches Ruima In Procedural Sedation In China
Brief: Paion Announces Successful Product Launch Of Anerem (Remimazolam) In Japan By Mundipharma
Brief: Paion Approval Of Compassionate Use Program For Remimazolam In Belgium
Brief: Paion: China's NMPA Grants Market Approval For Remimazolam For Use In Procedural Sedation
Brief: PAION U.S. License Agreement For BYFAVOTM Between Paion And Cosmo
Brief: Paion Reports Full Conversion Of Convertible Notes
Brief: Paion: US FDA Approval Of Remimazolam For Induction And Maintenance Of Procedural Sedation